Login to Your Account



Incyte quits Jakafi combination trial over insufficient efficacy

By Michael Fitzhugh
Staff Writer

Thursday, January 28, 2016

Unrest sowed by Incyte Corp.'s futility-driven stoppage of a phase II substudy testing Jakafi and Stivarga  against metastatic colorectal cancer helped drive company shares down 9.6 percent on Thursday.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription